Yang K, Zhao Y, Du Y, et al. - To clarify the contribution of the Hippo pathway and CD133 in radiation resistance in small-cell lung cancer (SCLC), researchers performed this first-of-a-kind study where they assessed the expression of key Hippo pathway proteins in SCLC patients via immunohistochemical staining, the involvement of yes-associated protein 1 (YAP1) in radiation resistance by using Cell Counting Kit-8 and flow cytometry, and determined how CD133 could influence radiotherapy for SCLC. In SCLC patients, no significant link with disease stage or survival time was shown by the mammalian Ste20-like serine/threonine kinase 2(MST2), pMST2, and pYAP1 in the Hippo pathway. However, some significance of the pYAP1 expression was noted in the “YAP/TAZ (transcriptional coactivator with PDZ-binding motif) subgroup” of SCLC patients. Overall, in SCLC patients, expression of key Hippo pathway proteins was documented and findings showed that the expression of YAP1 in the Hippo pathway may control CD133, and there may exist a link between CD133 and radiation resistance of SCLC.